Dopaminergic basis of salience dysregulation in psychosis

Trends in Neurosciences

Volumn 37, Issue 2, 2014, Pages 85-94

  Winton Brown, Toby T ^a   Fusar Poli, Paolo ^a,b   Ungless, Mark A ^c   Howes, Oliver D ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine; Psychosis; Reward; Salience; Schizophrenia

Indexed keywords

DOPAMINE; NEUROLEPTIC AGENT;

ANALYTICAL ERROR; ATTENTION; AVERSION; BEHAVIOR; BEHAVIOR CHANGE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; EMOTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LEARNING; MOLECULAR IMAGING; NEUROCHEMISTRY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; REWARD; SCHIZOPHRENIA; VISION;

DOPAMINE; PSYCHOSIS; REWARD; SALIENCE; SCHIZOPHRENIA;

DOPAMINERGIC NEURONS; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84893640696     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2013.11.003     Document Type: Review

References (124)

1. Carlsson A., et al. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180. 10.1038/1801200a0.
2. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.) 1963, 20:140-144.
3. Posner M.I., Petersen S.E. The attention system of the human brain. Annu. Rev. Neurosci. 1990, 13:25-42.
4. Redgrave P., et al. Functional properties of the basal ganglia's re-entrant loop architecture: selection and reinforcement. Neuroscience 2011, 198:138-151.
5. Nothdurft H. Salience from feature contrast: additivity across dimensions. Vision Res. 2000, 40:1183-1201.
6. Koch C., Ullman S. Shifts in selective visual attention: towards the underlying neural circuitry. Hum. Neurobiol. 1985, 4:219-227.
7. Li Z. A saliency map in primary visual cortex. Trends Cogn. Sci. 2002, 6:9-16.
8. Meger D., et al. Curious George: an attentive semantic robot. Robot. Auton. Syst. 2008, 56:503-511.
9. Redgrave P., et al. The basal ganglia: a vertebrate solution to the selection problem?. Neuroscience 1999, 89:1009-1023.
10. Haber S.N. The primate basal ganglia: parallel and integrative networks. J. Chem. Neuroanat. 2003, 26:317-330.
11. Wise R.A., Hoffman D.C. Localization of drug reward mechanisms by intracranial injections. Synapse 1992, 10:247-263.
12. Mora F., Myers R.D. Brain self-stimulation: direct evidence for the involvement of dopamine in the prefrontal cortex. Science 1977, 197:1387-1389.
13. Schultz W. Getting formal with dopamine and reward. Neuron 2002, 36:241-263.
14. Wise R.A. Dopamine, learning and motivation. Nat. Rev. Neurosci. 2004, 5:483-494.
15. Schultz W. Predictive reward signal of dopamine neurons. J. Neurophysiol. 1998, 80:1-27.
16. Steinberg E.E., et al. A causal link between prediction errors, dopamine neurons and learning. Nat. Neurosci. 2013, 16:966-973.
17. Fletcher P.C., Frith C.D. Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia. Nat. Rev. Neurosci. 2009, 10:48-58.
18. Robbins T.W., Sahakian B.J. Behavioral effects of psychomotor stimulant drugs: clinical and neuropsychological implications. Stimulants: Neurochemical, Behavioural and Clinical Perspective 1983,.301-338. Raven Press. I. Creese (Ed.).
19. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Rev. 1998, 28:309-369.
20. Flagel S.B., et al. A selective role for dopamine in stimulus-reward learning. Nature 2011, 469:53-57.
21. Ungless M.A. Dopamine: the salient issue. Trends Neurosci. 2004, 27:702-706.
22. Redgrave P., Gurney K. The short-latency dopamine signal: a role in discovering novel actions?. Nat. Rev. Neurosci. 2006, 7:967-975.
23. Schultz W. Dopamine signals for reward value and risk: basic and recent data. Behav. Brain Funct. 2010, 6:24-32.
24. Horvitz J.C. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience 2000, 96:651-656.
25. Dommett E., et al. How visual stimuli activate dopaminergic neurons at short latency. Science 2005, 307:1476-1479.
26. Kakade S., Dayan P. Dopamine: generalization and bonuses. Neural Netw. 2002, 15:549-559.
27. Bunzeck N., Duzel E. Absolute coding of stimulus novelty in the human substantia nigra/VTA. Neuron 2006, 51:369-379.
28. Schott B.H., et al. Activation of midbrain structures by associative novelty and the formation of explicit memory in humans. Learn. Mem. 2004, 11:383-387.
29. Wittmann B.C., et al. Anticipation of novelty recruits reward system and hippocampus while promoting recollection. Neuroimage 2007, 38:194-202.
30. Lisman J.E., Grace A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005, 46:703-713.
31. Joshua M. Midbrain dopaminergic neurons and striatal cholinergic interneurons encode the difference between reward and aversive events at different epochs of probabilistic classical conditioning trials. J. Neurosci. 2008, 28:11673-11684.
32. Thierry A.M. Influence of the mesocortical/prefrontal dopamine neurons on their target cells. Ann. N. Y. Acad. Sci. 1988, 537:101-111.
33. Abercrombie E.D. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J. Neurochem. 1989, 52:1655-1658.
34. Cabib S., Puglisi-Allegra S. The mesoaccumbens dopamine in coping with stress. Neurosci. Biobehav. Rev. 2012, 36:79-89.
35. Anstrom K.K.K., Woodward D.J.D. Restraint increases dopaminergic burst firing in awake rats. Neuropsychopharmacology 2005, 30:1832-1840.
36. Carter R.M., et al. Activation in the VTA and nucleus accumbens increases in anticipation of both gains and losses. Front. Behav. Neurosci. 2009, 3. 10.3389/neuro.08.021.2009.
37. Carstensen L.L., Turk-Charles S. The salience of emotion across the adult life span. Psychol. Aging 1994, 9:259-264.
38. Wittmann B.C., et al. Mesolimbic interaction of emotional valence and reward improves memory formation. Neuropsychologia 2008, 46:1000-1008.
39. Kienast T., et al. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat. Neurosci. 2008, 11:1381-1382.
40. Jabbi M., et al. Midbrain presynaptic dopamine tone predicts sustained and transient neural response to emotional salience in humans: fMRI, MEG and FDOPA PET. Mol. Psychiatry 2012, 10.1038/mp.2012.12.
41. Fiorillo C.D., et al. Diversity and homogeneity in responses of midbrain dopamine neurons. J. Neurosci. 2013, 33:4693-4709.
42. Brischoux F., et al. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:4894-4899.
43. Matsumoto M., Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 2009, 459:837-841.
44. Bromberg-Martin E.S., et al. Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 2010, 68:815-834.
45. Ungless M.A., et al. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 2004, 303:2040-2042.
46. Mileykovskiy B., Morales M. Duration of inhibition of ventral tegmental area dopamine neurons encodes a level of conditioned fear. J. Neurosci. 2011, 31:7471-7476.
47. Matsumoto M., Takada M. Distinct representations of cognitive and motivational signals in midbrain dopamine neurons. Neuron 2013, 79:1011-1024.
48. Fiorillo C.D. Two dimensions of value: dopamine neurons represent reward but not aversiveness. Science 2013, 341:546-549.
49. Valenti O., et al. Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J. Neurosci. 2011, 31:4280-4289.
50. Roitman M.F., et al. Real-time chemical responses in the nucleus accumbens differentiate rewarding and aversive stimuli. Nat. Neurosci. 2008, 11:1376-1377.
51. Budygin E.A., et al. Aversive stimulus differentially triggers subsecond dopamine release in reward regions. Neuroscience 2012, 201:331-337.
52. Brown H.D., et al. Primary food reward and reward-predictive stimuli evoke different patterns of phasic dopamine signaling throughout the striatum. Eur. J. Neurosci. 2011, 34:1997-2006.
53. Lammel S., et al. Input-specific control of reward and aversion in the ventral tegmental area. Nature 2012, 491:212-217.
54. Haber S.N.S., et al. Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum. J. Neurosci. 2000, 20:2369-2382.
55. Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci. Biobehav. Rev. 2010, 35:129-150.
56. Lodge D.J., Grace A.A. Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int. J. Neuropsychopharmacol. 2011, 10.1017/S1461145711000113.
57. Howes O.D., et al. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry Suppl. 2007, 51:s13-s18.
58. Howes O.D., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
59. Mishara A.L. Klaus Conrad (1905-1961): delusional mood, psychosis, and beginning schizophrenia. Schizophr. Bull. 2010, 36:9-13.
60. Jaspers K. General Psychopathology 1963, Manchester University Press. 7th edn.
61. Mishara A.L., Fusar-poli P. The phenomenology and neurobiology of delusion formation during psychosis onset: Jaspers, Truman symptoms, and aberrant salience. Schizophr. Bull. 2013, 10.1093/schbul/sbs155.
62. Fusar-poli P., et al. "Truman" signs and vulnerability to psychosis. Br. J. Psychiatry 2008, 193:168.
63. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
64. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
65. Kim K., et al. Schizophrenic delusions in Seoul, Shanghai and Taipei: a transcultural study. J. Korean Med. Sci. 2001, 16:88-94.
66. Lodge D.J., Grace A.A. Developmental pathology, dopamine, stress and schizophrenia. Int. J. Dev. Neurosci. 2011, 29:207-213.
67. Grace A.A. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J. Neural Transm. Suppl. 1992, 36:91-131.
68. Bunney B.S., Grace A.A. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci. 1978, 23:1715-1727.
69. Valenti O., et al. Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J. Neurosci. 2011, 31:12330-12338.
70. Hietala J., et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995, 346:1130-1131.
71. Reith J., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:11651-11654.
72. Hietala J., et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 1999, 35:41-50.
73. Kumakura Y., et al. Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J. Neurosci. 2007, 27:8080-8087.
74. 11C) DOPA and PET. Biol. Psychiatry 1999, 46:681-688.
75. 11C]-DOPA PET studies. Schizophr. Bull. 2012, 10.1093/schbul/sbr180.
76. Howes O.D., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment: meta-analysis of imaging studies. Arch. Gen. Psychiatry 2012, 10.1001/archgenpsychiatry.2012.169.
77. Egerton A., et al. The dopaminergic basis of human behaviors: a review of molecular imaging studies. Neurosci. Biobehav. Rev. 2009, 33:1109-1132.
78. Laruelle M., et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997, 17:162-174.
79. Abi-Dargham A., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
80. Breier A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2569-2574.
81. Laruelle M., et al. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 1999, 46:56-72.
82. Mizrahi R., et al. Increased stress-induced dopamine release in psychosis. Biol. Psychiatry 2012, 71:561-567.
83. Abi-Dargham A., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8104-8109.
84. Fusar-poli P., et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
85. 18F]-DOPA PET imaging study. Am. J. Psychiatry 2011, 168:1311-1317.
86. Egerton A., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74:106-112.
87. Huttunen J., et al. Striatal dopamine synthesis in first-degree relatives of patients with schizophrenia. Biol. Psychiatry 2008, 63:114-117.
88. Shotbolt P., et al. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol. Med. 2011, 41:2331-2338.
89. 18F]-DOPA imaging study in healthy individuals with auditory hallucinations. Schizophr. Bull. 2012, 10.1093/schbul/sbr195.
90. Howes O., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011, 10.1038/mp.2011.20.
91. Fusar-poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia. Part I: meta-analysis of dopamine active transporter (DAT) density. Schizophr. Bull. 2012, 10.1093/schbul/sbr111.
92. Bonoldi I., Howes O.D. The enduring centrality of dopamine in the pathophysiology of schizophrenia: in vivo evidence from the prodrome to the first psychotic episode. Adv. Pharmacol. 2013, 68:199-220.
93. Howes O.D., et al. Pathways to schizophrenia: the impact of environmental factors. Int. J. Neuropsychopharmacol. 2004, 7:S7-S13.
94. Juckel G., et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
95. Schlagenhauf F., et al. Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol. Psychiatry 2009, 65:1032-1039.
96. Juckel G., et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006, 187:222-228.
97. Waltz J.A., et al. Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 2010, 35:2427-2439.
98. Morris R.W., et al. Disambiguating ventral striatum fMRI-related bold signal during reward prediction in schizophrenia. Mol. Psychiatry 2012, 17:280-289.
99. Nielsen M.Ø., et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol. Psychiatry 2012, 71:898-905.
100. Murray G.K., et al. Substantia nigra/ventral tegmental reward prediction error disruption in psychosis. Mol. Psychiatry 2008, 13:239-276.
101. Roiser J.P., et al. Adaptive and aberrant reward prediction signals in the human brain. Neuroimage 2010, 50:657-664.
102. Roiser J.P., et al. Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophr. Bull. 2012, 10.1093/schbul/sbs147.
103. Jensen J., et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008, 33:473-479.
104. Haralanova E., et al. Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2012, 262:59-68.
105. Taylor S.F., et al. Neural response to emotional salience in schizophrenia. Neuropsychopharmacology 2005, 30:984-995.
106. Holt D.J., et al. The misattribution of salience in delusional patients with schizophrenia. Schizophr. Res. 2006, 83:247-256.
107. Diaconescu A.O., et al. Aberrant effective connectivity in schizophrenia patients during appetitive conditioning. Front. Hum. Neurosci. 2011, 4:239.
108. Howes O.D., et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15:2550-2559.
109. Nordström A.L., et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry 1993, 33:227-235.
110. Kapur S., et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157:514-520.
111. Leucht S., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
112. McCabe C., et al. The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers. Psychopharmacology 2011, 217:271-278.
113. Jocham G., et al. Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices. J. Neurosci. 2011, 31:1606-1613.
114. Pessiglione M., et al. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006, 442:1042-1045.
115. Stone J.M., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatry 2010, 68:599-602.
116. Stone J.M., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
117. Cifelli P., Grace A.A. Pilocarpine-induced temporal lobe epilepsy in the rat is associated with increased dopamine neuron activity. Int. J. Neuropsychopharmacol. 2012, 15:957-964.
118. Angrist B.M., Gershon S. The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol. Psychiatry 1970, 2:95-107.
119. Yui K., et al. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann. N. Y. Acad. Sci. 2006, 914:1-12.
120. Schlagenhauf F., et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008, 196:673-684.
121. Abler B., et al. Abnormal reward system activation in mania. Neuropsychopharmacology 2008, 33:2217-2227.
122. Walter H., et al. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berl) 2009, 206:121-132.
123. Simon J.J., et al. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr. Res. 2010, 118:154-161.
124. Koch K., et al. Altered activation in association with reward-related trial-and-error learning in patients with schizophrenia. Neuroimage 2010, 50:223-232.